According to the RNC Pharma® database “Audit of Retail Sales of Veterinary Medicinal Products in Russia (total sell-out)”, in Q1–Q3 2025, more than 215 million minimum dosage units (MDU) of veterinary medicines were sold on the Russian retail market (including online), representing a 15% increase compared to the same period of the previous year, when consumption reached 186.6 million MDU. The value of retail veterinary sales in the first nine months of 2025 reached RUB 38.3 billion (in retail prices, including VAT), marking a 16.1% increase in ruble terms versus January–September 2024.

Over the past nine months, seasonal peaks in demand for animal medicines were less pronounced than a year earlier. Traditionally, demand for veterinary products rises in spring, but in 2025 an unusually warm spring triggered an early seasonal surge. Sales volumes increased sharply in early March, with demand peaks recorded in April and August. The August sales volume in MDUs set a historical record, reaching 26.3 million units, compared to 22.1 million in August 2024.

Importantly, the current market growth is entirely driven by domestically produced veterinary medicines. Compared with Q1–Q3 2024, sales of Russian-made products rose by 37.2% in value and 30.3% in volume, while sales of imported products declined by 2.3% in value and 13.3% in volume over the same period.

In April 2025, total consumer spending on Russian veterinary medicines exceeded RUB 3 billion, surpassing imports for the first time. Over the next six months, domestic products maintained monthly sales volumes above RUB 2.3 billion, whereas foreign-made medicines failed to exceed RUB 2 billion per month.

Two Russian manufacturers — Ekoprom and Agrovetzashchita — together accounted for over 36% of the total value of domestic veterinary medicine sales. Compared to January–September 2024, these companies recorded growth of 11% and 17%, respectively. However, the fastest growth among the top 10 domestic producers was shown by Vetpharmstandard, whose only product, Tixfli, launched in August 2024, resulted in a 608-fold sales increase year-on-year. Also notable were Vetbiokhim, whose vaccines Multican and Multifel saw value sales grow 2.1x and 2.4x, respectively.

Among foreign manufacturers, the U.S. company Zoetis retained its leadership in the Russian veterinary retail market, accounting for 28.4% of total imported product sales (in ruble terms). It was followed by KRKA (Slovenia, 21.3%) and Elanco (U.S., 16.9%). Among the top 10 international suppliers, Belarus-based Belekotechnika demonstrated the highest growth, with sales increasing by 49% in value and 23% in volume during the reporting period.